Live Biotherapeutics Drug Discovery Service for Ventilator Associated Pneumonia
Overview
With the increasingly serious problem of multi-drug resistant pathogens, there are fewer and fewer treatment options, and clinicians pay more and more attention to the adoption of effective prevention strategies. Ventilator-associated pneumonia (VAP) is the most common hospital-acquired infection. Its pathogenesis is complex but mainly involves two important processes: bacterial colonization of the upper gastrointestinal tract and inhalation of contaminated secretions into the lower airways. Endogenous bacterial flora plays an important role in the occurrence and development of VAP. The migration of potential pathogenic bacteria in the upper gastrointestinal tract and abnormal colonization are considered to be the main mechanisms of VAP. The occurrence and development of VAP involve ecological dysbiosis and the failure of the host immune response. Several studies have evaluated a variety of strategies to prevent VAP, including pharmacological and non-pharmacological interventions, and scientists have proposed a novel intervention for the treatment of VAP with probiotics. Although the prevention of VAP by probiotics does not eradicate pathogenic microorganisms as well as antibiotics, it can delay the time of bacterial colonization, and probiotic treatment can provide a non-antibiotic strategy to reduce the risk of VAP.
Probiotics for the Prevention of VAP
Probiotics are an effective non-antibiotic intervention to reduce the occurrence of VAP, even those caused by multi-drug-resistant bacteria. Probiotics are effective in reducing the length of hospital stay, gastric residual volume, and microbiologically confirmed VAP, and their use may be beneficial in restoring the stability of the endogenous flora and preventing VAP. Factors such as species, strains, dose, route, and duration of administration of probiotics should be carefully considered when evaluating their effectiveness in relieving VAP.
Mechanism of Probiotics Acting on VAP
Metabolites of probiotics include short-chain fatty acids and antimicrobial substances such as bacteriocins, as well as micro bacteriocins that can inhibit the growth or kill pathogens. Most probiotics synthesize acetate and lactic acid, which can reduce the pH in the gut and thus inhibit the growth of bacteria such as Pseudomonas and Enterobacteriaceae. It has been reported that probiotics can reduce the incidence of VAP in critically ill patients by reducing pathogen overgrowth, improving intestinal barrier function, inhibiting pathogen adhesion, reducing bacterial translocation, and up-regulating immune function.
Our Services for VAP Research
|
Research Article
|
Available Services
|
|
Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice.1
|
|
With more than a dozen years of experience in contract research services, Creative Biolabs is a leading global service provider. We offer a cost-effective way to complete your project. We can prepare probiotics according to the customer's animal study protocol, and can also perform antibacterial testing, antibiotic resistance analysis, and mouse treatment experiments on your target probiotics. If you do not find the services and products you are interested in on our website, please contact us directly for details.
Reference
-
Fangous, Marie-Sarah, et al. "Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice." BMC microbiology 21 (2021): 1-11. Distributed Under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
